HC Wainwright Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its price objective dropped by stock analysts at HC Wainwright from $240.00 to $180.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 7.89% from the stock’s current price.

Several other analysts also recently issued reports on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Stock Down 0.6 %

Shares of NASDAQ:RGEN opened at $166.84 on Thursday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a 50 day moving average of $149.17 and a two-hundred day moving average of $145.43. The company has a market capitalization of $9.35 billion, a price-to-earnings ratio of -450.91, a price-to-earnings-growth ratio of 4.51 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the company earned $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, analysts forecast that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in RGEN. Champlain Investment Partners LLC lifted its stake in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after buying an additional 36,773 shares during the last quarter. DF Dent & Co. Inc. lifted its stake in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Repligen by 14.4% in the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after buying an additional 71,274 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.